Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051844 · ClinicalTrials.gov registry record · Phase 2
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT00051844 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 179 participants.
The verdict
NCT00051844, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Interventions
- DRUG Capravirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2002-08 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051844
The ClinicalTrials.gov registry entry for NCT00051844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capravirine is the first listed.
NCT00051844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051844 about?
NCT00051844 is a clinical study titled "Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen". This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
What is the current status of trial NCT00051844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2002-08. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00051844?
The interventions under investigation include: Capravirine (DRUG).
Who is sponsoring clinical trial NCT00051844?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.